Skip to content
Colorectal Cancer Clinical Trials

Nebraska

Colorectal cancer clinical trials in Nebraska

31 colorectal cancer studies are recruiting participants at sites in 9 cities across Nebraska as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Nebraska city with a recruiting study

Omaha (27), Grand Island (7), Kearney (7), Lincoln (5), Bellevue (1), Hastings (1), Norfolk (1), North Platte (1), Papillion (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Nebraska

Basic details from each study's public record (the 12 most recently updated of 31). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Omaha
    Registry record
    NCT06997497 · updated
  2. Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Recruiting in
    Grand Island · Omaha · Papillion
    Registry record
    NCT07750158 · updated
  3. Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Recruiting in
    Grand Island · Kearney · Omaha
    Registry record
    NCT07018869 · updated
  4. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Lincoln
    Registry record
    NCT07228832 · updated
  5. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Recruiting in
    Grand Island · Kearney · Omaha
    Registry record
    NCT05080673 · updated
  6. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Recruiting in
    Kearney · Lincoln · Omaha
    Registry record
    NCT05174169 · updated
  7. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Recruiting in
    Grand Island · Kearney · Omaha
    Registry record
    NCT05334069 · updated
  8. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Recruiting in
    Kearney
    Registry record
    NCT06418204 · updated
  9. Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Recruiting in
    Grand Island · Kearney · Omaha
    Registry record
    NCT07283939 · updated
  10. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Recruiting in
    Bellevue · Omaha
    Registry record
    NCT05673148 · updated
  11. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Omaha
    Registry record
    NCT06662786 · updated
  12. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Omaha
    Registry record
    NCT06750094 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Nebraska on ClinicalTrials.gov.

Ask about studies in Nebraska

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call